Seralite
Seralite® is a rapid diagnostic device for the quantitative measurement of kappa (K) and lambda (λ) immunoglobulin free light chains (FLCs) in serum. The assay utilises highly specific, anti-K and anti-λ monoclonal antibodies which are conjugated to gold particles and incorporated into a simple to use lateral flow device. Utilising a portable reader the results are presented on screen in mg/L along with the calculated K/λ rati…
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
Seralite® is a rapid diagnostic device for the quantitative measurement of kappa (K) and lambda (λ) immunoglobulin free light chains (FLCs) in serum. The assay utilises highly specific, anti-K and anti-λ monoclonal antibodies which are conjugated to gold particles and incorporated into a simple to use lateral flow device. Utilising a portable reader the results are presented on screen in mg/L along with the calculated K/λ ratio.
Seralite® provides an accurate picture of disease status in 10 minutes. With this simple to use, portable, rapid test, clinicians are able to monitor patients in “real time” supporting faster decision making.
The measurement of FLCs for diagnosis and monitoring of myeloma and related disorders has been widely published. As a result of these many years of research, UK, European and International guidelines recommend the measurement of serum FLCs.
As FLCs have a short half-life of a few hours, changes to tumour load and the response to chemotherapy can be observed more rapidly by measuring FLCs. This rapid test provides the clinician with an accurate picture of disease status within minutes rather than days, supporting faster decision making.
FLCs are also recommended as prognostic indicators in Monoclonal Gammopathy of Undetermined Significance (MGUS). In MGUS the FLC ratio is helpful in identifying individuals who are at an increased risk of progression to Multiple Myeloma and related disorders. Using Seralite in a clinic setting can allow improved management of patients with MGUS.
Development of a Highly-Sensitive Multiplex Assay Using Monoclonal Antibodies for the Measurement of Kappa and Lambda Free Light Chains in Serum and Urine
Despite the enormous advantages offered by commercial assays to measure κ and λ immunoglobulin free light chains (FLC), a number of analytical limitations can be attributed to the use of sheep polyclonal antisera as capture antibodies. A second generation test using monoclonal antibodies (mAbs) is desirable. This poster describes a highly-sensitive multiplex assay which uses mAbs for the simultaneous measurement of FLC's in urine and serum.
Utilization of Immunoglobulin Free Light Chains as a Biomarker of B Cell Dysregulation in HIV Patients: Quantitation Using a New Rapid Test (Seralite®)
HIV-infected individuals have B cell dysregulation which contributes to immunodeficiency and risk of AIDS progression and B cell Non-Hodgkins Lymphoma. B cell dysregulation is characterized by an increased production of intact immunoglobulins (e.g. IgA, IgM, IgG) and free light chains (FLC). FLCs are regarded as a more sensitive marker of B cell activation status. This poster describes a study to assess the clinical utility of measuring FLC levels in HIV-infected individuals using a new and cost-effective rapid lateral-flow test that quantitates serum FLC in 10 minutes.
Validation of a New Rapid Free-Light-Chain Test (Seralite®) for the Diagnosis and Monitoring of Plasma Cell Dyscrasias
Monoclonal kappa (κ) or lambda (λ) immunoglobulin free light chains (FLC), produced from malignant plasma cell clones, are important biomarkers for the diagnosis and monitoring of plasma cell dyscrasias, including multiple myeloma. This poster shows that the rapid assay, Seralite®, has superior diagnostic sensitivity compared to immunofixation electrophoresis, and can provide clinically valid quantitation of κ and λ FLC in serum and urine within 10 minutes.
Development of a Rapid Test for the Measurement of Kappa and Lambda Free Light Chains in Serum and Urine from Patients with Myeloma Kidney
At present, laboratory free light chain tests offer the only means of quantitating kappa and lambda free light chains (FLC) and have a slow turnaround time that prevents early diagnosis of myeloma kidney, and increases the risk of kidney failure. This poster shows that a new rapid test (Seralite™) is capable of rapidly identifying abnormal FLC levels in blood, providing precise quantitation of FLC is serum and urine within 10 minutes.
